Incentives for New Drugs to Tackle Anti-Microbial Resistance
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
- Hollis, Aidan & Ahmed, Ziana, 2014. "The path of least resistance: Paying for antibiotics in non-human uses," Health Policy, Elsevier, vol. 118(2), pages 264-270.
- Jorge Mestre-Ferrandiz;Jon Sussex;Adrian Towse, 2012. "The R&D Cost of a New Medicine," Monograph 000135, Office of Health Economics.
- Karlsberg Schaffer, S. & West, P. & Towse, A. & Henshall, C. & Mestre-Ferrandiz, J. & Masterson, R. & Fischer, A., 2017. "Additional Elements of Value for Health Technology Assessment Decisions," Briefings 001851, Office of Health Economics.
- Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 185-208, April.
- Richard, Oliver & Van Horn, Larry, 2004. "Persistence in prescriptions of branded drugs," International Journal of Industrial Organization, Elsevier, vol. 22(4), pages 523-540, April.
- Andrew S Robertson & Rianna Stefanakis & Don Joseph & Melinda Moree, 2012. "The Impact of the US Priority Review Voucher on Private-Sector Investment in Global Health Research and Development," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 6(8), pages 1-5, August.
- Michael Kremer, 2002. "Pharmaceuticals and the Developing World," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 67-90, Fall.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Towse, Adrian & Hoyle, Christopher K. & Goodall, Jonathan & Hirsch, Mark & Mestre-Ferrandiz, Jorge & Rex, John H., 2017. "Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation," Health Policy, Elsevier, vol. 121(10), pages 1025-1030.
- Coburn, Josie & Bone, Frederique & Hopkins, Michael M. & Stirling, Andy & Mestre-Ferrandiz, Jorge & Arapostathis, Stathis & Llewelyn, Martin J., 2021. "Appraising research policy instrument mixes: a multicriteria mapping study in six European countries of diagnostic innovation to manage antimicrobial resistance," Research Policy, Elsevier, vol. 50(4).
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
- Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
- Sanzenbacher, Geoffrey T. & Wettstein, Gal, 2020. "Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D," Journal of Health Economics, Elsevier, vol. 72(C).
- Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
- Banerjee, Tannista & Siebert, Ralph, 2017. "Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry," Research Policy, Elsevier, vol. 46(7), pages 1255-1271.
- Fossett, Sarah J. & Wunnava, Phanindra V., 2017. "Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs," IZA Discussion Papers 10817, Institute of Labor Economics (IZA).
- Jonathan Dando & Maximilian Lebmeier, 2020. "A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-speci," Journal of Innovation and Entrepreneurship, Springer, vol. 9(1), pages 1-28, December.
- Ingo Stiller & Arjen Witteloostuijn & Bart Cambré, 2022. "Determinants of radical drug innovation: a systematic literature review," Management Review Quarterly, Springer, vol. 72(4), pages 967-1016, December.
- Venkatanarayana Motkuri & Rudra Narayan Mishra, 2020. "Pharmaceutical Market and Drug Price Policy in India," Review of Development and Change, , vol. 25(1), pages 30-53, June.
- Chakraborty, Shankha & Papageorgiou, Chris & Pérez Sebastián, Fidel, 2010.
"Diseases, infection dynamics, and development,"
Journal of Monetary Economics, Elsevier, vol. 57(7), pages 859-872, October.
- Chris Papageorgiou & Fidel Pérez Sebastián & Shankha Chakraborty, 2010. "Diseases, infection dynamics and development," Working Papers. Serie AD 2010-28, Instituto Valenciano de Investigaciones Económicas, S.A. (Ivie).
- Dosis, Anastasios & Muthoo, Abhinay, 2019.
"Experimentation in Dynamic R&D Competition,"
CRETA Online Discussion Paper Series
52, Centre for Research in Economic Theory and its Applications CRETA.
- Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," The Warwick Economics Research Paper Series (TWERPS) 1214, University of Warwick, Department of Economics.
- Anastasios, Dosis & Abhinay, Muthoo, 2019. "Experimentation in Dynamic R&D Competition," ESSEC Working Papers WP1901, ESSEC Research Center, ESSEC Business School.
- Anastasios Dosis & Abhinay Muthoo, 2019. "Experimentation in Dynamic R&D Competition," Working Papers hal-02102518, HAL.
- Yusuke Oh & Koji Takahashi, 2020. "R&D and Innovation: Evidence from Patent Data," Bank of Japan Working Paper Series 20-E-7, Bank of Japan.
- Harsha Thirumurthy & Joshua Graff Zivin & Markus Goldstein, 2008.
"The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya,"
Journal of Human Resources, University of Wisconsin Press, vol. 43(3), pages 511-552.
- Harsha Thirumurthy & Joshua Graff-Zivin & Markus Goldstein, 2005. "The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya," NBER Working Papers 11871, National Bureau of Economic Research, Inc.
- Thirumurthy, Harsha & Zivin, Joshua Graff & Goldstein, Markus, 2006. "The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya," Center Discussion Papers 28414, Yale University, Economic Growth Center.
- Harsha Thirumurthy & Joshua Graff Zivin & Markus Goldstein, 2006. "The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya," Working Papers 947, Economic Growth Center, Yale University.
- Harsha Thirumurthy, 2005. "The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya," Working Papers id:300, eSocialSciences.
- Eric W. Bond & Kamal Saggi, 2023.
"Compulsory licensing, price controls, and access to patented foreign products,"
World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 19, pages 437-448,
World Scientific Publishing Co. Pte. Ltd..
- Bond, Eric W. & Saggi, Kamal, 2014. "Compulsory licensing, price controls, and access to patented foreign products," Journal of Development Economics, Elsevier, vol. 109(C), pages 217-228.
- Eric Saggi & Saggi Saggi, 2012. "Compulsory licensing, price controls, and access to patented foreign products," Vanderbilt University Department of Economics Working Papers 12-00006, Vanderbilt University Department of Economics.
- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022.
"Generic competition and the incentives for early-stage pharmaceutical innovation,"
Research Policy, Elsevier, vol. 51(10).
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
- Lucy Xiaolu Wang, 2023. "A cost-benefit analysis of the medicines patent pool," Economics Bulletin, AccessEcon, vol. 43(3), pages 1298-1319.
- Daniel Tobias Michaeli & Thomas Michaeli & Sebastian Albers & Tobias Boch & Julia Caroline Michaeli, 2024. "Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(6), pages 979-997, August.
- Unsal, Omer & Houston, Reza, 2024. "R&D grants and medical innovation," Journal of Economics and Business, Elsevier, vol. 128(C).
- Teteryatnikova, Mariya, 2018.
"R&D in trade networks: The role of asymmetry,"
International Journal of Industrial Organization, Elsevier, vol. 61(C), pages 307-350.
- Mariya Teteryatnikova, 2016. "R&D in trade Networks: The Role of Asymmetry," Vienna Economics Papers 1601, University of Vienna, Department of Economics.
More about this item
Keywords
Incentives for New Drugs to Tackle Anti-Microbial Resistance;JEL classification:
- I1 - Health, Education, and Welfare - - Health
NEP fields
This paper has been announced in the following NEP Reports:- NEP-COM-2018-05-21 (Industrial Competition)
- NEP-HEA-2018-05-21 (Health Economics)
- NEP-IPR-2018-05-21 (Intellectual Property Rights)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:briefg:001842. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Publications Manager (email available below). General contact details of provider: https://edirc.repec.org/data/ohecouk.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.